UNSPSC 51282936: Pazufloxacin

This classification denotes a quinolone antibiotic with the molecular formula C16H15FN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4CZ1R38NDI, chemically known as 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-, (s)- but generally known as pazufloxacin, which bears US NIH Compound Identifier 65957. European Medicines Agency schedules Pazufloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09641MIG.

UNSPSC 51282936 Pazufloxacin is a Commodity code for a specific fluoroquinolone antibiotic, yet recent state and local procurement activity under this code shows minimal direct alignment with the narrow product scope. State and local health departments and counties appear to use this code or related pharmaceutical taxonomy codes when procuring antibiotics and other pharmaceuticals through piggyback and cooperative purchasing vehicles. The actual work being solicited spans the procurement of antibiotics and related pharmaceutical products in bulk quantities for state health agency warehouses and county health systems. Issuing bodies include state departments of public health and county health authorities operating through existing pharmaceutical purchasing consortia and cooperative agreements.

Geographic activity is concentrated in the Midwest and Southeast, with recent visibility in Illinois and Florida. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, totaling $2,999,999.11 over three years, for supply of Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets via an Invitation for Bid (IFB) process—note that neither antibiotic is pazufloxacin, reflecting frequent misalignment between assigned codes and the pharmaceutical products actually being procured. Seminole County, Florida issued an IFB on June 30, 2026 (IFB60459723LAS) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries, with a response deadline of July 26, 2023. Code activity is sparse and does not show sustained open procurement of pazufloxacin specifically; opportunities under this UNSPSC appear episodic and often reflect broader antibiotic or pharmaceutical warehouse stocking rather than targeted demand for this particular drug formulation.